Searched for
HALEON NRT PORTFOLIO
DRL gears up for biosimilar push, consumer health growth post record FY25Dr Reddy’s stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, biosimilar launc...- Dr Reddy's net profit rises 2% to Rs 1,413 crore in Q3FY25Dr. Reddy's reported a 2% YoY profit increase to ₹1,413 crore in Q3 FY25, with revenue rising 16% to ₹8,359 crore. North America sales grew...
- Dr Reddy's completes acquisition of Haleon's NRT portfolioDr Reddy's Laboratories has acquired Haleon's global Nicotine Replacement Therapy (NRT) portfolio, excluding the US, for GBP 458 million. T...
- Dr Reddy's to buy nicotine replacement brands from UK-based Haleon for $632 millionThe portfolio to be acquired consists of Nicotinell, a global leader in the NRT category with an extensive footprint in over 30 countries s...
Load More